

# Keith A Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5227545/publications.pdf>

Version: 2024-02-01

370  
papers

23,443  
citations

14124

69  
h-index

10679

143  
g-index

441  
all docs

441  
docs citations

441  
times ranked

21313  
citing authors

#	ARTICLE	IF	CITATIONS
1	Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2023, 19, 169-180.	0.4	11
2	Plasma IL-12/IFN- $\beta$ axis predicts cognitive trajectories in cognitively unimpaired older adults. <i>Alzheimer's and Dementia</i> , 2022, 18, 645-653.	0.4	39
3	Current directions in tau research: Highlights from Tau 2020. <i>Alzheimer's and Dementia</i> , 2022, 18, 988-1007.	0.4	42
4	Effect of vascular amyloid on white matter disease is mediated by vascular dysfunction in cerebral amyloid angiopathy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1272-1281.	2.4	9
5	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
6	Variant-dependent heterogeneity in amyloid $\beta$ burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. <i>Lancet Neurology</i> , The, 2022, 21, 140-152.	4.9	34
7	Impact of 40-Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1667-1676.	1.2	22
8	Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI. <i>Neurology</i> , 2022, 98, .	1.5	10
9	Lower novelty-related locus coeruleus function is associated with $\beta$ -related cognitive decline in clinically healthy individuals. <i>Nature Communications</i> , 2022, 13, 1571.	5.8	32
10	Association of Emerging $\beta$ -Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults. <i>Neurology</i> , 2022, 98, .	1.5	20
11	Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid- $\beta$ and Tau Pathology in Middle-Aged Adults: The Framingham Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1371-1383.	1.2	18
12	Amyloid- $\beta$ and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2113641119.	3.3	26
13	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 592.	4.5	29
14	Associations Between Brainstem Volume and Alzheimer's Disease Pathology in Middle-Aged Individuals of the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1603-1609.	1.2	0
15	Menopause Status Moderates Sex Differences in Tau Burden: A Framingham PET Study. <i>Annals of Neurology</i> , 2022, 92, 11-22.	2.8	29
16	Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1517-1526.	1.2	8
17	Association of $\beta$ -Amyloid and Vascular Risk on Longitudinal Patterns of Brain Atrophy. <i>Neurology</i> , 2022, 99, .	1.5	8
18	Association of Aortic Stiffness and Pressure Pulsatility With Global Amyloid- $\beta$ and Regional Tau Burden Among Framingham Heart Study Participants Without Dementia. <i>JAMA Neurology</i> , 2022, 79, 710.	4.5	10

#	ARTICLE	IF	CITATIONS
19	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. <i>Acta Neuropathologica</i> , 2022, 144, 589-601.	3.9	32
20	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 426-438.	1.2	30
21	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. <i>Neurology</i> , 2021, 96, e619-e631.	1.5	45
22	Attenuation correction using deep Learning and integrated UTE/multi-echo Dixon sequence: evaluation in amyloid and tau PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1351-1361.	3.3	14
23	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 27.	3.0	34
24	Association of Digital Clock Drawing With PET Amyloid and Tau Pathology in Normal Older Adults. <i>Neurology</i> , 2021, 96, e1844-e1854.	1.5	38
25	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 813-821.	0.4	8
26	Association of Memory Impairment With Concomitant Tau Pathology in Patients With Cerebral Amyloid Angiopathy. <i>Neurology</i> , 2021, 96, e1975-e1986.	1.5	16
27	Association of Midlife Depressive Symptoms with Regional Amyloid- $\beta^2$ and Tau in the Framingham Heart Study. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 249-260.	1.2	9
28	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	18
29	Longitudinal predictive modeling of tau progression along the structural connectome. <i>NeuroImage</i> , 2021, 237, 118126.	2.1	8
30	Association of cortical microstructure with amyloid- $\beta^2$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
31	In vivo and neuropathology data support locus coeruleus integrity as indicator of Alzheimer's disease pathology and cognitive decline. <i>Science Translational Medicine</i> , 2021, 13, eabj2511.	5.8	107
32	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	111
33	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, eabh1448.	4.7	70
34	18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. <i>Brain</i> , 2021, 144, 266-277.	3.7	7
35	Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD. <i>Current Alzheimer Research</i> , 2021, 18, 711-720.	0.7	6
36	Longitudinal Trajectories of Participant- and Study Partner-Rated Cognitive Decline, in Relation to Alzheimer's Disease Biomarkers and Mood Symptoms. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 806432.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 800126.	1.7	19
38	AHEAD 3&#x2014;45 study: Preliminary screening and baseline characteristics from a placebo&#x2014;controlled, double&#x2014;blind study evaluating lecanemab in participants with preclinical Alzheimer&#x2019;s disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
39	Blood phosphorylated tau 181 predicts early, preclinical brain amyloid deposition. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
40	Brainstem volume is negatively associated with amyloid deposition in the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
41	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
42	Associations between biomarker status (amyloid, tau) and risk for progression to MCI/Dementia in the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
43	Locus coeruleus integrity as a proxy of initial tau burden: in vivo versus ex vivo observations. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
44	Amyloid&#x2014; <sup>12</sup> and tau pathologies relate to distinctive brain dysconnectomics in autosomal&#x2014;dominant Alzheimer&#x2019;s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
45	Extraneous neuroimaging factors do not contribute to sex differences in flortaucipir signal: Analysis of skull binding and partial volume effects. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
46	Associations between remote cognitive testing on an individual&#x2019;s own digital device and amyloid burden on neuroimaging in clinically normal older adults: Results from Boston Remote Assessment for Neurocognitive Health (BRANCH). <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
47	<sup>18</sup> F&#x2014;Flortaucipir PET imaging compared with autopsy in a clinically and pathologically heterogeneous group of patients with neurodegenerative dementias. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
48	Sequential early cognitive changes sensitive to rising beta&#x2014;amyloid and tau pathology in preclinical AD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
49	Longitudinal associations between amyloid and tau&#x2014;PET: Impact for prevention trials. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
50	Associations between plasma p&#x2014;tau <sub>217</sub> , in vivo brain pathology and cognition in individuals with autosomal&#x2014;dominant Alzheimer&#x2019;s disease: Findings from the Columbia&#x2014;Boston (COLBOS) biomarker study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
51	Self&#x2014;reported history of estrogen hormone therapy differentiates rates of amyloid accumulation (PiB&#x2014;PET) relative to males: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
52	Amygdala tau pathology in preclinical autosomal dominant Alzheimer&#x2019;s disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
53	The combined influence of beta&#x2014;amyloid and vascular risk on prospective brain atrophy in clinically normal individuals. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
54	Longitudinal trajectories of remote assessment of self&#x2014;and study partner&#x2014;rated cognitive concerns, mood and Alzheimer&#x2019;s disease biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
55	Monthly computerized at-home assessments to detect cognitive change in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
56	Regional beta-amyloid and tau deposition: Results from the Framingham Heart Study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
57	Association between the Harvard automated phone task and Alzheimer's disease pathology in clinically normal older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
58	Multimodal neuroimaging biomarkers of Alzheimer's disease in older adults with depression: Preliminary findings from a pilot cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
59	The location of <i>PSEN1</i> pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
60	Locus coeruleus integrity predicts tau accumulation and memory dysfunction in autosomal dominant Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e052664.	0.4	0
61	Heterogeneity of tau deposition and microvascular involvement in MCI and AD.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054282.	0.4	0
62	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. <i>Molecular Psychiatry</i> , 2020, 25, 2599-2607.	4.1	28
63	Longitudinal degradation of the default/saliency network axis in symptomatic individuals with elevated amyloid burden.. <i>NeuroImage: Clinical</i> , 2020, 26, 102052.	1.4	18
64	Functional and Pathological Correlates of Judgments of Learning in Cognitively Unimpaired Older Adults. <i>Cerebral Cortex</i> , 2020, 30, 1974-1983.	1.6	7
65	Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, 552-560.	0.4	55
66	Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 330-332.	0.9	7
67	Resting-state functional connectivity and amyloid burden influence longitudinal cortical thinning in the default mode network in preclinical Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2020, 28, 102407.	1.4	23
68	Multiple markers contribute to risk of progression from normal to mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2020, 28, 102400.	1.4	8
69	Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals. <i>Nature Communications</i> , 2020, 11, 6024.	5.8	43
70	Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. <i>JAMA Neurology</i> , 2020, 77, 1504.	4.5	48
71	Sex Mediates Relationships Between Regional Tau Pathology and Cognitive Decline. <i>Annals of Neurology</i> , 2020, 88, 921-932.	2.8	63
72	The neurophysiology and seizure outcomes of late onset unexplained epilepsy. <i>Clinical Neurophysiology</i> , 2020, 131, 2667-2672.	0.7	9

#	ARTICLE	IF	CITATIONS
73	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 104.	3.0	7
74	Visual short-term memory relates to tau and amyloid burdens in preclinical autosomal dominant Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 99.	3.0	22
75	Tracking the origin of tau spread in the brain. <i>Alzheimer's and Dementia</i> , 2020, 16, e037501.	0.4	0
76	Memory impairment is a clinical marker of tau pathology in cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e037524.	0.4	0
77	Alzheimer's disease biomarker roadmap 2020: [ 18 F]florataucipir. <i>Alzheimer's and Dementia</i> , 2020, 16, e039550.	0.4	0
78	Alzheimer's disease biomarker roadmap 2020: Second-generation tau PET tracers. <i>Alzheimer's and Dementia</i> , 2020, 16, e039556.	0.4	1
79	Sex, tau, and cortical thinning in the temporal lobe: Findings from the Harvard Aging Brain Study. <i>Alzheimer's and Dementia</i> , 2020, 16, e040031.	0.4	0
80	Grip strength and gait speed as early biomarkers of brain amyloid and tau deposition. <i>Alzheimer's and Dementia</i> , 2020, 16, e041178.	0.4	2
81	Hypoconnectivity between locus coeruleus and medial temporal lobe during novelty predicts accelerated $\beta$ -related cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e041323.	0.4	2
82	The relationship between cortical microstructural changes and in vivo amyloid $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
83	Longitudinal inferior temporal FTP-PET signal increase is associated with contemporaneous longitudinal temporal lobe cortical thinning in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e043419.	0.4	0
84	Estimating an individual's placement on a theoretical continuum using longitudinal cognitive trajectories: Relationships with longitudinal amyloid and Tau-PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e043566.	0.4	0
85	Associations of peak width of skeletonized mean diffusivity with cardiovascular disease risk and cognitive decline in clinically normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e043812.	0.4	0
86	Plasma IL-12/IFN- $\beta$ axis predicts cognitive trajectories in cognitively normal older adults. <i>Alzheimer's and Dementia</i> , 2020, 16, e045497.	0.4	0
87	Distinct contributions of longitudinal tau and amyloid to decline in various cognitive domains in preclinical AD. <i>Alzheimer's and Dementia</i> , 2020, 16, e046075.	0.4	0
88	Alzheimer's disease biomarker roadmap 2020: Time for tau. <i>Alzheimer's and Dementia</i> , 2020, 16, e039549.	0.4	3
89	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 138.	3.0	14
90	Examining Cognitive Decline Across Black and White Participants in the Harvard Aging Brain Study. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1437-1446.	1.2	18

#	ARTICLE	IF	CITATIONS
91	Association Between Common Variants in <i>RBFox1</i> , an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 1288.	4.5	41
92	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. <i>Neurology</i> , 2020, 94, e1916-e1928.	1.5	13
93	Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 142, 104960.	2.1	31
94	Inferior temporal tau is associated with accelerated prospective cortical thinning in clinically normal older adults. <i>NeuroImage</i> , 2020, 220, 116991.	2.1	31
95	Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. <i>Neurology</i> , 2020, 95, e1312-e1321.	1.5	7
96	Associations of Widowhood and $\beta$ -Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. <i>JAMA Network Open</i> , 2020, 3, e200121.	2.8	27
97	Word retrieval across the biomarker-confirmed Alzheimer's disease syndromic spectrum. <i>Neuropsychologia</i> , 2020, 140, 107391.	0.7	17
98	Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2020, 77, 735.	4.5	182
99	Amyloid-beta burden predicts prospective decline in body mass index in clinically normal adults. <i>Neurobiology of Aging</i> , 2020, 93, 124-130.	1.5	27
100	MR-based PET attenuation correction using a combined ultrashort echo time/multi-echo Dixon acquisition. <i>Medical Physics</i> , 2020, 47, 3064-3077.	1.6	12
101	Topography of cortical thinning in the Lewy body diseases. <i>NeuroImage: Clinical</i> , 2020, 26, 102196.	1.4	15
102	The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. <i>Annals of Neurology</i> , 2019, 85, 181-193.	2.8	171
103	Longitudinal Association of Depression Symptoms With Cognition and Cortical Amyloid Among Community-Dwelling Older Adults. <i>JAMA Network Open</i> , 2019, 2, e198964.	2.8	72
104	Associations of Physical Activity and $\beta$ -Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 1203.	4.5	97
105	Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [ $^{18}\text{F}$ ]MK6240 in human subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2099-2111.	3.3	26
106	Amyloid imaging of dutch-type hereditary cerebral amyloid angiopathy carriers. <i>Annals of Neurology</i> , 2019, 86, 616-625.	2.8	22
107	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. <i>Neurology</i> , 2019, 93, e476-e484.	1.5	23
108	Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2019, 36, 3233-3243.	1.7	21

#	ARTICLE	IF	CITATIONS
109	[18F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. <i>Acta Neuropathologica Communications</i> , 2019, 7, 164.	2.4	33
110	Graph Convolutional Neural Networks For Alzheimer's Disease Classification. , 2019, 2019, 414-417.		55
111	Using subjective cognitive decline to identify high global amyloid in community-based samples: A cross-cohort study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 670-678.	1.2	19
112	Regional Tau Correlates of Instrumental Activities of Daily Living and Apathy in Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 757-768.	1.2	32
113	Measuring instrumental activities of daily living in non-demented elderly: a comparison of the new performance-based Harvard Automated Phone Task with other functional assessments. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 4.	3.0	9
114	Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. <i>JAMA Neurology</i> , 2019, 76, 542.	4.5	201
115	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease. <i>JAMA Neurology</i> , 2019, 76, 915.	4.5	512
116	Visual cognition in non-amnesic Alzheimer's disease: Relations to tau, amyloid, and cortical atrophy. <i>NeuroImage: Clinical</i> , 2019, 23, 101889.	1.4	17
117	Social Engagement and Amyloid- $\beta$ -Related Cognitive Decline in Cognitively Normal Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2019, 27, 1247-1256.	0.6	56
118	Synergism between fornix microstructure and beta amyloid accelerates memory decline in clinically normal older adults. <i>Neurobiology of Aging</i> , 2019, 81, 38-46.	1.5	17
119	O300 Linking Sleep Disturbances with Amyloid and Tau Imaging. Preliminary Findings from the Harvard Aging Brain Study. <i>Sleep</i> , 2019, 42, A122-A123.	0.6	0
120	PET Image Deblurring and Super-Resolution With an MR-Based Joint Entropy Prior. <i>IEEE Transactions on Computational Imaging</i> , 2019, 5, 530-539.	2.6	27
121	An UNC5C Allele Predicts Cognitive Decline and Hippocampal Atrophy in Clinically Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1161-1170.	1.2	5
122	Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation in cerebrospinal fluid. <i>Neurobiology of Aging</i> , 2019, 78, 178-185.	1.5	54
123	Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. <i>Acta Neuropathologica Communications</i> , 2019, 7, 37.	2.4	105
124	Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 14.	3.0	26
125	Striatal amyloid is associated with tauopathy and memory decline in familial Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 17.	3.0	26
126	ICP-178: SEX DIFFERENCES IN TAU PATHOLOGY ACROSS CORTICAL AND SUBCORTICAL REGIONS OF INTEREST: FINDINGS ACROSS TWO COHORTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P139.	0.4	0



#	ARTICLE	IF	CITATIONS
127	P4â€Pâ€07: FREE AND CUED MEMORY IS DISTINCTLY RELATED TO PATHOLOGY IN PRECLINICAL AUTOSOMALâ€DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
128	ICâ€Pâ€037: GERIATRIC DEPRESSION SCALE ITEMâ€LEVEL ANALYSIS IN RELATION TOâ€IN VIVO</i> CORTICAL AMYLOID AND CEREBRAL REGIONAL TAU IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2019, 15, P43.	0.4	0
129	ICâ€Pâ€089: ASSOCIATIONS OF REGIONAL CORTICAL THINNING AND LONGITUDINAL COGNITIVE PERFORMANCE IN THE CONTEXT OF AMYLOID IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2019, 15, P79.	0.4	0
130	F2â€03â€01: CLINICAL MEANINGFULNESS OF SHORTâ€TERM COGNITIVE DECLINE ON THE PRECLINICAL ALZHEIMER'S COGNITIVE COMPOSITEâ€5 (PACCâ€5) IN NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID. Alzheimer's and Dementia, 2019, 15, P518.	0.4	0
131	ICâ€Pâ€008: ANATOMICAL STAGING OF BETAâ€AMYLOID ACCUMULATION BASED ON LONGITUDINAL ASSESSMENT OF GLOBALLY PIB NEGATIVE ADULTS. Alzheimer's and Dementia, 2019, 15, P18.	0.4	0
132	ICâ€Pâ€067: TOPOGRAPHY OF CORTICAL THINNING IN THE LEWY BODY DEMENTIAS. Alzheimer's and Dementia, 2019, 15, P63.	0.4	0
133	P4â€608: TAU ACCUMULATION AND VISUAL MEMORY IN COGNITIVELY UNIMPAIRED PSEN1 E280A MUTATION CARRIERS. Alzheimer's and Dementia, 2019, 15, P1557.	0.4	0
134	Resistance to autosomal dominant Alzheimerâ€™s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine, 2019, 25, 1680-1683.	15.2	328
135	ICâ€Pâ€058: COVARYING SPATIAL PATTERNS OF TAU DEPOSITION AND GRAY MATTER ATROPHY UNEARTHED BY THE INFORMED MULTIMODAL PARTIAL LEAST SQUARES (MMPLS) IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: FINDINGS FROM THE COLBOS PROJECT. Alzheimer's and Dementia, 2019, 15, P58.	0.4	0
136	O3â€09â€01: PROTECTIVE EFFECT OF PHYSICAL ACTIVITY ON LONGITUDINAL COGNITIVE DECLINE AND NEURODEGENERATION IN CLINICALLY NORMAL OLDER ADULTS WITH ELEVATED Î²â€AMYLOID BURDEN. Alzheimer's and Dementia, 2019, 15, P903.	0.4	0
137	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. NeuroImage: Clinical, 2019, 24, 102097.	1.4	7
138	Anticholinergic Amnesia is Mediated by Alterations in Human Network Connectivity Architecture. Cerebral Cortex, 2019, 29, 3445-3456.	1.6	12
139	Vascular Risk and <b>Î²</b>â€Amyloid Are Synergistically Associated with Cortical Tau. Annals of Neurology, 2019, 85, 272-279.	2.8	75
140	Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity. Journal of Neuroscience, 2019, 39, 548-556.	1.7	75
141	Nonlinear Distributional Mapping (NoDiM) for harmonization across amyloid-PET radiotracers. NeuroImage, 2019, 186, 446-454.	2.1	16
142	Global White Matter Diffusion Characteristics Predict Longitudinal Cognitive Change Independently of Amyloid Status in Clinically Normal Older Adults. Cerebral Cortex, 2019, 29, 1251-1262.	1.6	47
143	PET imaging of tau protein targets: a methodology perspective. Brain Imaging and Behavior, 2019, 13, 333-344.	1.1	43
144	Preferential degradation of cognitive networks differentiates Alzheimerâ€™s disease from ageing. Brain, 2018, 141, 1486-1500.	3.7	79

#	ARTICLE	IF	CITATIONS
145	18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. Journal of Alzheimer's Disease, 2018, 62, 1691-1702.	1.2	67
146	Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nature Neuroscience, 2018, 21, 424-431.	7.1	198
147	Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 548.	4.5	137
148	The relationship between recall of recently versus remotely encoded famous faces and amyloidosis in clinically normal older adults. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 121-129.	1.2	11
149	Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults. American Journal of Psychiatry, 2018, 175, 530-537.	4.0	175
150	Flortaucipir tau PET imaging in semantic variant primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1024-1031.	0.9	80
151	Interactive versus additive relationships between regional cortical thinning and amyloid burden in predicting clinical decline in mild AD and MCI individuals. NeuroImage: Clinical, 2018, 17, 388-396.	1.4	8
152	ICA-P&A041: LONGITUDINAL CHANGE OF FUNCTIONAL CONNECTIVITY IN PRECLINICAL AD: RESULTS FROM THE HARVARD AGING BRAIN STUDY. Alzheimer's and Dementia, 2018, 14, P41.	0.4	1
153	O1&A08&A03: DIGITIZED CLOCK DRAWING (DTCLOCK<sup>TM</sup>) PERFORMANCE AND ITS RELATIONSHIP TO AMYLOID AND TAU PET IMAGING MARKERS IN UNIMPAIRED OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P236.	0.4	1
154	O3&A12&A01: DECREASED META&A0MEMORY FOR EPISODIC BUT NOT SEMANTIC INFORMATION IS ASSOCIATED WITH EARLY TAUOPATHY IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1050.	0.4	0
155	P1&A327: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P417.	0.4	0
156	P3&A090: JOINT DEBLURRING OF LONGITUDINAL DIFFERENTIAL PET IMAGES OF TAU. Alzheimer's and Dementia, 2018, 14, P1100.	0.4	0
157	P3&A370: AN APOE&A04 DERIVED STATISTICAL METHOD FOR OPTIMIZING TARGET AND REFERENCE REGIONS FOR AMYLOID&A0PET IMAGING. Alzheimer's and Dementia, 2018, 14, P1231.	0.4	0
158	P3&A290: AMYLOID PATHOLOGY EXPLAINS UNAWARENESS OF MEMORY DEFICITS ABOVE AND BEYOND CORTICAL THICKNESS IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P1191.	0.4	0
159	O1&A02&A02: THE ANTI&A0AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMER'S DISEASE (A4) STUDY: REPORT OF SCREENING DATA RESULTS. Alzheimer's and Dementia, 2018, 14, P215.	0.4	3
160	O3&A04&A03: AMYLOID IS ASSOCIATED WITH GREATER TAU BURDEN IN CLINICALLY NORMAL FEMALES RELATIVE TO MALES: FINDINGS FROM TWO INDEPENDENT COHORTS. Alzheimer's and Dementia, 2018, 14, P1019.	0.4	0
161	O1&A02&A01: IMPACT OF DISCLOSING AMYLOID IMAGING RESULTS TO COGNITIVELY NORMAL RESEARCH PARTICIPANTS: THE A4 EXPERIENCE. Alzheimer's and Dementia, 2018, 14, P215.	0.4	0
162	P1&A443: ASSOCIATION BETWEEN REGIONAL AMYLOID AND REGIONAL TAU IN YOUNGER, NON&A0DEMENTED INDIVIDUALS IN THE FRAMINGHAM HEART STUDY. Alzheimer's and Dementia, 2018, 14, P482.	0.4	0

#	ARTICLE	IF	CITATIONS
163	P1â€Pâ€159: LOCUS COERULEUS SIGNAL INTENSITY IS ASSOCIATED WITH ENTORHINAL TAU PATHOLOGY AT HIGHER LEVELS OF AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P509.	0.4	1
164	ICâ€Pâ€206: QUANTITATIVE SCORING OF [18F] FLORTAUCIPIR PET SCANS IN TYPICAL AND ATYPICAL PHENOTYPES OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P170.	0.4	0
165	ICâ€Pâ€159: BRAIN RESILIENCE PROTECTS AGAINST COGNITIVE DECLINE ASSOCIATED WITH ELEVATED AMYLOID BURDEN. Alzheimer's and Dementia, 2018, 14, P134.	0.4	0
166	F4â€08â€02: AMYLOID BURDEN AND VASCULAR RISK ARE INDEPENDENTLY ASSOCIATED WITH SUBJECTIVE COGNITIVE DECLINE IN CLINICALLY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P1394.	0.4	0
167	ICâ€Pâ€138: ASSOCIATION BETWEEN REGIONAL AMYLOID AND REGIONAL TAU WITHIN YOUNGER, NONâ€DEMENTED INDIVIDUALS OF THE FRAMINGHAM HEART STUDY. Alzheimer's and Dementia, 2018, 14, P115.	0.4	0
168	P2â€452: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONDEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P892.	0.4	0
169	O1â€02â€05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS. Alzheimer's and Dementia, 2018, 14, P217.	0.4	0
170	O1â€10â€03: SEX AND <i>APOE</i> GENOTYPE INFLUENCE THE ASSOCIATION BETWEEN AMYLOID AND LONGITUDINAL TAU PATHOLOGY IN CLINICALLY NORMAL OLDER ADULTS: FINDINGS FROM THE ADNI STUDY. Alzheimer's and Dementia, 2018, 14, P243.	0.4	0
171	ICâ€Pâ€215: TAU ACCUMULATION IN RHINAL CORTEX IS ASSOCIATED WITH MEMORY PERFORMANCE IN NONâ€DEMENTED YOUNG ADULTS WITH AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P176.	0.4	0
172	ICâ€Pâ€139: LONGITUDINAL DEPRESSIVE SYMPTOMS AND CORTICAL AMYLOID ARE ASSOCIATED WITH COGNITIVE DECLINE IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P116.	0.4	0
173	P4â€118: AV1451 TAU PET, BUT NOT CSF TAU, IS RELATED TO MEMORY DECLINE IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1484.	0.4	0
174	ICâ€02â€04: REGIONAL ASYMMETRIES IN AMYLOID AND TAU GO TOGETHER: EVIDENCE FOR LOCAL INTERACTION. Alzheimer's and Dementia, 2018, 14, P4.	0.4	1
175	P1â€301: CERTAIN PLASMA Nâ€TERMINAL TAU FRAGMENTS ARE ELEVATED IN AD AND ADâ€MCI COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P405.	0.4	0
176	ICâ€Pâ€140: TAU ACCUMULATION AND MEMORY DECLINE ARE MORE CLOSELY RELATED TO STRIATAL THAN CORTICAL AMYLOIDOSIS IN INDIVIDUALS WITH EARLYâ€ONSET AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P117.	0.4	0
177	P2â€461: ENTORHINAL TAU PATHOLOGY IS ASSOCIATED WITH WHITE MATTER ABNORMALITIES IN UNCINATE FASCICULUS IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P897.	0.4	0
178	ICâ€Pâ€203: JOINT DEBLURRING OF LONGITUDINAL DIFFERENTIAL PET IMAGES OF TAU. Alzheimer's and Dementia, 2018, 14, P167.	0.4	0
179	ICâ€Pâ€147: QUANTIFYING STAGES OF SUBTLE MEMORY IMPAIRMENT IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P125.	0.4	1
180	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	2.4	46

#	ARTICLE	IF	CITATIONS
181	O <sub>2</sub> â€08â€06: AMYLOIDâ€ $\beta$ , COGNITION AND SOCIAL ACTIVITY IN COGNITIVELY NORMAL OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P640.	0.4	0
182	Amyloidâ€associated increases in longitudinal report of subjective cognitive complaints. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 444-449.	1.8	51
183	Neurogenetic contributions to amyloid beta and tau spreading in the human cortex. Nature Medicine, 2018, 24, 1910-1918.	15.2	135
184	Dedifferentiation of caudate functional connectivity and striatal dopamine transporter density predict memory change in normal aging. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 10160-10165.	3.3	49
185	Interactive Associations of Vascular Risk and $\beta$ -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. JAMA Neurology, 2018, 75, 1124.	4.5	165
186	PET staging of amyloidosis using striatum. Alzheimer's and Dementia, 2018, 14, 1281-1292.	0.4	93
187	Threshold Regression to Accommodate a Censored Covariate. Biometrics, 2018, 74, 1261-1270.	0.8	9
188	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ€™s disease. PLoS ONE, 2018, 13, e0195838.	1.1	51
189	Impaired memory is more closely associated with brain beta-amyloid than leukoaraiosis in hypertensive patients with cognitive symptoms. PLoS ONE, 2018, 13, e0191345.	1.1	11
190	P3â€399: ASSOCIATION BETWEEN CORTICAL THINNING AND TAU PATHOLOGY IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1253.	0.4	0
191	Harvard Aging Brain Study: Dataset and accessibility. NeuroImage, 2017, 144, 255-258.	2.1	107
192	Case 1-2017. New England Journal of Medicine, 2017, 376, 158-167.	13.9	17
193	Linear Regression with a Randomly Censored Covariate: Application to an Alzheimer's Study. Journal of the Royal Statistical Society Series C: Applied Statistics, 2017, 66, 313-328.	0.5	16
194	Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology, 2017, 88, 1431-1438.	1.5	46
195	Association of In Vivo [ <sup>18</sup> F]AV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease. JAMA Neurology, 2017, 74, 427.	4.5	236
196	Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid $\beta$ . Alzheimer's and Dementia, 2017, 13, 1004-1012.	0.4	139
197	Fluorodeoxyglucose metabolism associated with tauâ€amyloid interaction predicts memory decline. Annals of Neurology, 2017, 81, 583-596.	2.8	110
198	Regional 18F-Fluorodeoxyglucose Hypometabolism is Associated with Higher Apathy Scores Over Time in Early Alzheimer Disease. American Journal of Geriatric Psychiatry, 2017, 25, 683-693.	0.6	37

#	ARTICLE	IF	CITATIONS
199	Neuroimaging markers associated with maintenance of optimal memory performance in late-life. <i>Neuropsychologia</i> , 2017, 100, 164-170.	0.7	35
200	Functional network integrity presages cognitive decline in preclinical Alzheimer disease. <i>Neurology</i> , 2017, 89, 29-37.	1.5	106
201	The association between tau PET and retrospective cortical thinning in clinically normal elderly. <i>NeuroImage</i> , 2017, 157, 612-622.	2.1	74
202	Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. <i>NeuroImage: Clinical</i> , 2017, 15, 408-414.	1.4	61
203	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. <i>JAMA Neurology</i> , 2017, 74, 813.	4.5	61
204	Tau and amyloid $\beta$ proteins distinctively associate to functional network changes in the aging brain. <i>Alzheimer's and Dementia</i> , 2017, 13, 1261-1269.	0.4	90
205	Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease. <i>Neuropsychologia</i> , 2017, 99, 343-349.	0.7	67
206	Hippocampal hypometabolism in older adults with memory complaints and increased amyloid burden. <i>Neurology</i> , 2017, 88, 1759-1767.	1.5	50
207	Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. <i>Journal of Neuroscience</i> , 2017, 37, 4323-4331.	1.7	237
208	Epicenters of dynamic connectivity in the adaptation of the ventral visual system. <i>Human Brain Mapping</i> , 2017, 38, 1965-1976.	1.9	4
209	The influence of demographic factors on subjective cognitive concerns and beta-amyloid. <i>International Psychogeriatrics</i> , 2017, 29, 645-652.	0.6	17
210	Pathological correlations of $^{18}\text{F}$ -AV-451 imaging in non-Alzheimer tauopathies. <i>Annals of Neurology</i> , 2017, 81, 117-128.	2.8	174
211	Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global $\beta$ -Amyloid Burden. <i>JAMA Neurology</i> , 2017, 74, 1455.	4.5	119
212	<sup>18</sup> F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. <i>Annals of Neurology</i> , 2017, 82, 622-634.	2.8	148
213	Partial volume correction for PET quantification and its impact on brain network in Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 13035.	1.6	37
214	Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1451-1459.	1.2	80
215	[S20101]: IMAGING AMYLOID AND TAU PATHOLOGY: LESSONS LEARNED. <i>Alzheimer's and Dementia</i> , 2017, 13, P541.	0.4	0
216	[O40706]: <i>IN VIVO</i> SPREADING PATHWAYS OF TAU AND AMYLOID ACCUMULATION AND ITS GENETIC UNDERPINNINGS. <i>Alzheimer's and Dementia</i> , 2017, 13, P1246.	0.4	0

#	ARTICLE	IF	CITATIONS
217	Cognitive resilience in clinical and preclinical Alzheimer's disease: the Association of Amyloid and Tau Burden on cognitive performance. <i>Brain Imaging and Behavior</i> , 2017, 11, 383-390.	1.1	54
218	Pharmacokinetic Evaluation of the Tau PET Radiotracer <sup>18</sup> F-T807 ( <sup>18</sup> F-AV-1451) in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 484-491.	2.8	73
219	[P3376]: QRISK2 AND FRAMINGHAM CARDIOVASCULAR RISK SCORES SIGNIFICANTLY CORRELATE WITH IMAGING BIOMARKERS OF PRECLINICAL AD: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1103.	0.4	1
220	[P4228]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1357.	0.4	0
221	[P4243]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1369.	0.4	0
222	[ICP41]: SAMPLE SIZES FOR 24-MONTH ALZHEIMER'S PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P36.	0.4	0
223	[ICP089]: ANXIETY, SUBJECTIVE COGNITIVE DECLINE, AND CORTICAL AMYLOID IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P72.	0.4	0
224	[ICP108]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. <i>Alzheimer's and Dementia</i> , 2017, 13, P85.	0.4	0
225	[ICP181]: LONGITUDINAL TAU ACCUMULATION IS ASSOCIATED WITH COGNITIVE DECLINE IN NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P134.	0.4	2
226	[IC0203]: TAU AND HIPPOCAMPAL VOLUME REFLECT DISTINCT PROCESSES IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P5.	0.4	1
227	[P1256]: BASELINE CARDIOVASCULAR RISK AND AMYLOID BURDEN SYNERGISTICALLY PREDICT LONGITUDINAL COGNITIVE DECLINE IN CLINICALLY NORMAL ELDERLY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P347.	0.4	0
228	[P1398]: TAU ACCUMULATION IS DETECTABLE AND CORRELATED TO AMYLOID BURDEN IN NORMAL AND IMPAIRED OLDER INDIVIDUALS USING SERIAL PET. <i>Alzheimer's and Dementia</i> , 2017, 13, P423.	0.4	0
229	[P1434]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMAL-DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P448.	0.4	0
230	[P2298]: ASSOCIATIONS BETWEEN MEASURES OF MEDIAL TEMPORAL LOBE NEURODEGENERATION AND ANOSOGNOSIA FOR MEMORY DEFICITS. <i>Alzheimer's and Dementia</i> , 2017, 13, P730.	0.4	0
231	[F10302]: SUBJECTIVE COGNITIVE DECLINE, LONGITUDINAL COGNITIVE PERFORMANCE, AND IMAGING BIOMARKERS IN PRECLINICAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P176.	0.4	0
232	[O10205]: GENOTYPIC VARIANCE MAY EXPLAIN THE BALANCE OF EARLY CORTICAL VERSUS STRIATAL AMYLOID DEPOSITION IN AUTOSOMAL DOMINANT AD. <i>Alzheimer's and Dementia</i> , 2017, 13, P187.	0.4	1
233	[O21003]: SEVERITY OF SUBJECTIVE COGNITIVE DECLINE ALIGNS WITH REGIONAL AMYLOID SEVERITY: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P577.	0.4	0
234	[O21104]: COGNITIVE RESERVE RELATES TO GREATER FUNCTIONAL CONNECTIVITY AND STRONGER INTERCONNECTIVITY WITHIN AND BETWEEN NODES, INDEPENDENT OF AMYLOID: FINDINGS FROM THE HARVARD AGING BRAIN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P582.	0.4	0

#	ARTICLE	IF	CITATIONS
235	[O3â€“06â€“02]: SEMANTIC MEMORY AND PET AMYLOID AND TAU DEPOSITION IN PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P911.	0.4	0
236	[O3â€“07â€“06]: THE RELATIONSHIP BETWEEN RECALL OF RECENTLY VERSUS REMOTELY ENCODED FAMOUS FACES AND AMYLOID AND TAU BURDEN IN CLINICALLY NORMAL OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2017, 13, P917.	0.4	0
237	[P4â€“500]: SPATIAL PATTERNS OF FLORTAUCIPIR (FTP) SIGNAL IN COGNITIVELY NORMAL ELDERLY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1530.	0.4	1
238	Depressive Symptoms and Tau Accumulation in the Inferior Temporal Lobe and Entorhinal Cortex in Cognitively Normal Older Adults: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 975-985.	1.2	70
239	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinsonâ€™s case. <i>Acta Neuropathologica Communications</i> , 2017, 5, 75.	2.4	85
240	[P1â€“030]: RELATIONSHIPS BETWEEN MEMORY FUNCTION, TAU PATHOLOGY AND FUNCTIONAL CONNECTIVITY IN THE DEFAULT MODE NETWORK IN AUTOSOMAL-DOMINANT ALZHEIMER'S DISEASE: A PRELIMINARY REPORT. <i>Alzheimer's and Dementia</i> , 2017, 13, P245.	0.4	0
241	Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2017, 4, 81-86.	1.5	8
242	Multiple Brain Markers are Linked to Age-Related Variation in Cognition. <i>Cerebral Cortex</i> , 2016, 26, 1388-1400.	1.6	146
243	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimerâ€™s Disease: Results from the DIAN Study Group. <i>PLoS ONE</i> , 2016, 11, e0152082.	1.1	45
244	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
245	Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity. <i>Human Brain Mapping</i> , 2016, 37, 621-631.	1.9	24
246	P3â€“309: Profiles of Cognitive Decline Associated with Biomarker-Defined Preclinical Stages of Alzheimerâ€™s Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P960.	0.4	0
247	Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1097-1105.	1.2	44
248	P3-275: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. , 2016, 12, P940-P941.		0
249	P4-217: Regional Fluorodeoxyglucose Hypometabolism is Associated With Greater Apathy Over Time in Early Alzheimer's Disease. , 2016, 12, P1111-P1111.		0
250	F5-05-02: The Harvard Automated Phone Task (APT): A Novel Performance-Based ADL Instrument for Early Alzheimerâ€™s Disease. , 2016, 12, P373-P373.		1
251	ICâ€“Pâ€“013: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. <i>Alzheimer's and Dementia</i> , 2016, 12, P20.	0.4	1
252	IC-P-043: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P36-P37.		1

#	ARTICLE	IF	CITATIONS
253	ICâ€Pâ€053: Regional Fluorodeoxyglucose Hypometabolism is Associated with Greater Apathy Over Time in Early Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P43.	0.4	0
254	P2-341: Subjective Cognitive Decline Predicts Longitudinal Decline in those with Both Amyloidosis and Neurodegeneration. , 2016, 12, P773-P774.		0
255	P3-322: Optimal Memory Performance in Older Adults is Associated with Differences in Hippocampal Volume and Amyloid Status at Baseline and Over 3 Years. , 2016, 12, P969-P969.		0
256	ICâ€Pâ€185: The Effect of Tractâ€S Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P135.	0.4	0
257	ICâ€Pâ€190: Increased TAU PET Signal Associated with Longitudinal Mr Atrophy in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P137.	0.4	0
258	F1â€04â€01: Longitudinal Performance on the Preclinical Alzheimerâ€™s Cognitive Composite (PACC) in Subjects with Biomarkerâ€Defined Preclinical ad. Alzheimer's and Dementia, 2016, 12, P167.	0.4	0
259	O1â€13â€01: Anxiety, Social Activity and Amyloid in Cognitively Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P208.	0.4	0
260	F3-04-01: In Vivo Cortical Distribution of Tau and Amyloid Deposits in Cognitively Normal Elderly. , 2016, 12, P274-P274.		0
261	O3â€08â€03: The Effect of Tractâ€S Specific Loss of White Matter Connectivity on Cognitive Decline in Healthy Older Individuals Depends on Entorhinal T807 Binding. Alzheimer's and Dementia, 2016, 12, P304.	0.4	0
262	O3â€09â€03: Associations between Amyloidosis and Longitudinal Cognitive Decline in Clinically Normal Older Adults. Alzheimer's and Dementia, 2016, 12, P308.	0.4	0
263	O4â€01â€02: Tau and Amyloid Pet Imaging in a Colombian Kindred with Autosomalâ€Dominant Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P330.	0.4	0
264	O4â€01â€06: Ab+ Clinically Normal Participants with Elevated Tau Show Greatest Decline in the Preclinical Alzheimerâ€™s Disease Cognitive Composite. Alzheimer's and Dementia, 2016, 12, P333.	0.4	0
265	O4-06-04: Neuroimaging Correlates of Anosognosia in Mild Cognitive Impairment. , 2016, 12, P345-P346.		0
266	O4â€07â€05: Pet Staging of Amyloidosis: Evidence that Amyloid Occurs First in Neocortex and Later in Striatum. Alzheimer's and Dementia, 2016, 12, P349.	0.4	0
267	P4-325: TAU BURDEN is Associated with Subjective Cognitive Concerns in the Context of Î²-Amyloid Burden in Preclinical ad. , 2016, 12, P1158-P1159.		0
268	Accelerated decline in white matter integrity in clinically normal individuals at risk for Alzheimer's disease. Neurobiology of Aging, 2016, 42, 177-188.	1.5	57
269	Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. Lancet Neurology, The, 2016, 15, 811-819.	4.9	96
270	Florbetapir-PET to diagnose cerebral amyloid angiopathy. Neurology, 2016, 87, 2043-2049.	1.5	79



#	ARTICLE	IF	CITATIONS
271	Episodic memory of odors stratifies Alzheimer biomarkers in normal elderly. <i>Annals of Neurology</i> , 2016, 80, 846-857.	2.8	36
272	Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016, 12, 1288-1296.	0.4	23
273	Tau positron emission tomographic imaging in aging and early Alzheimer disease. <i>Annals of Neurology</i> , 2016, 79, 110-119.	2.8	778
274	Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly. <i>Neurology</i> , 2016, 87, 920-926.	1.5	86
275	Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. <i>JAMA Neurology</i> , 2016, 73, 1185.	4.5	52
276	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. <i>Journal of Neuroscience</i> , 2016, 36, 7364-7374.	1.7	153
277	IC-198: TAU and Amyloid PET Imaging in a Colombian Kindred with Autosomal-Dominant Alzheimer's Disease. <i>Alzheimer's and Dementia</i> , 2016, 12, P143.	0.4	0
278	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. <i>JAMA Psychiatry</i> , 2016, 73, 1230.	6.0	164
279	<i>Trans</i> -pQTL study identifies immune crosstalk between Parkinson and Alzheimer loci. <i>Neurology: Genetics</i> , 2016, 2, e90.	0.9	31
280	Multiple imputation of a randomly censored covariate improves logistic regression analysis. <i>Journal of Applied Statistics</i> , 2016, 43, 2886-2896.	0.6	5
281	Maternal dementia age at onset in relation to amyloid burden in non-demented elderly offspring. <i>Neurobiology of Aging</i> , 2016, 40, 61-67.	1.5	11
282	Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging. <i>NeuroImage</i> , 2016, 132, 334-343.	2.1	216
283	Matched signal detection on graphs: Theory and application to brain imaging data classification. <i>NeuroImage</i> , 2016, 125, 587-600.	2.1	34
284	Biomarker validation of a decline in semantic processing in preclinical Alzheimer's disease. <i>Neuropsychology</i> , 2016, 30, 624-630.	1.0	60
285	IC-P-084: Neurobiological correlates of anosognosia in mild cognitive impairment: A multimodal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P60-P60.		0
286	IC-P-125: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P85-P86.		0
287	P4-083: Hippocampal metabolism is decreased in high-amyloid mild cognitive impairment but not in high-amyloid clinically normal elders. , 2015, 11, P802-P803.		0
288	P4-064: Longitudinal 18 F-T807 PET imaging in a case of nonfluent variant primary progressive aphasia. , 2015, 11, P791-P792.		1

#	ARTICLE	IF	CITATIONS
289	IC-P-071: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P53-P53.		0
290	IC-P-085: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P60-P61.		0
291	O4-01-01: Regional Tau PET measures associated with memory performance in clinically normal older individuals. , 2015, 11, P265-P265.		1
292	Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2015, 46, 63-73.	1.2	87
293	IC-P-156: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P105-P105.		0
294	P3-162: Instrumental activities of daily living and functional connectivity in mild cognitive impairment. , 2015, 11, P690-P691.		0
295	IC-P-162: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P109-P109.		2
296	F3-03-03: Disclosure of amyloid status in the a4 trial. , 2015, 11, P215-P215.		1
297	O4-01-03: Entorhinal tau deposition is associated with parietal association cortex hypometabolism in clinically normal older individuals. , 2015, 11, P266-P267.		0
298	Validating novel tau positron emission tomography tracer [ <sup>18</sup> F]AV-1451 (T807) on postmortem brain tissue. Annals of Neurology, 2015, 78, 787-800.	2.8	535
299	The Apathy Evaluation Scale: A Comparison of Subject, Informant, and Clinician Report in Cognitively Normal Elderly and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 421-432.	1.2	65
300	Neuropsychiatric Symptoms and Functional Connectivity in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 46, 727-735.	1.2	44
301	A Spectral Graph Regression Model for Learning Brain Connectivity of Alzheimer's Disease. PLoS ONE, 2015, 10, e0128136.	1.1	35
302	Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia, 2015, 73, 169-175.	0.7	57
303	IC-P-068: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P51-P51.		1
304	F3-02-02: Snap in cognitively normal adults. , 2015, 11, P213-P213.		0
305	P2-141: Neurobiological correlates of anosognosia in mild cognitive impairment: A multi-modal investigation using FDG-PET, PiB-PET, and volumetric MRI. , 2015, 11, P540-P540.		0
306	O3-09-06: Location, location, location: The distributed effects of amyloid on functional connectivity in the harvard aging brain study. , 2015, 11, P240-P240.		0

#	ARTICLE	IF	CITATIONS
307	O5-01-01: Tau and amyloid deposits relate to distinctive cortical atrophy patterns in cognitively normal elderly. , 2015, 11, P311-P312.		0
308	P3-135: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P675-P676.		0
309	IC-P-153: Clinical and neuroimaging predictors of psychological well-being as measured by the purpose in life scale in cognitively normal older individuals. , 2015, 11, P102-P103.		0
310	P2-151: Imaging tau pathology in vivo in ftdl with [18F] T807 PET. , 2015, 11, P545-P545.		0
311	O1-06-05: Baseline amyloid PET imaging, longitudinal amyloid accumulation, and Tau PET imaging in preclinical Alzheimer's disease. , 2015, 11, P139-P139.		0
312	O2-02-03: The relationship of cognition, cognitive reserve, and in vivo tau and amyloid burden. , 2015, 11, P175-P175.		0
313	O2-02-05: Differential declines in letter versus category fluency over 4 years in biomarker-defined preclinical Alzheimer's disease. , 2015, 11, P176-P177.		0
314	O4-01-04: Entorhinal, parahippocampal, and inferior temporal F18-T807 SUVR correlates with CSF total tau and tau T181P in cognitively normal elderly. , 2015, 11, P267-P267.		1
315	O4-01-05: The relationship between cortical atrophy and tau pathology measured in vivo with [18F] T807 PET. , 2015, 11, P267-P268.		0
316	The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's and Dementia, 2015, 11, 1.	0.4	603
317	Amyloid- $\beta^2$ deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 2015, 138, 1023-1035.	3.7	207
318	Cognitive activity relates to cognitive performance but not to Alzheimer disease biomarkers. Neurology, 2015, 85, 48-55.	1.5	36
319	Subjective cognitive concerns, amyloid- $\beta^2$ , and neurodegeneration in clinically normal elderly. Neurology, 2015, 85, 56-62.	1.5	127
320	Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimer's Research and Therapy, 2015, 7, 26.	3.0	106
321	Odor identification and Alzheimer disease biomarkers in clinically normal elderly. Neurology, 2015, 84, 2153-2160.	1.5	120
322	CD33 modulates TREM2: convergence of Alzheimer loci. Nature Neuroscience, 2015, 18, 1556-1558.	7.1	134
323	Estimating Total Cerebral Microinfarct Burden From Diffusion-Weighted Imaging. Stroke, 2015, 46, 2129-2135.	1.0	52
324	Partial volume correction in quantitative amyloid imaging. NeuroImage, 2015, 107, 55-64.	2.1	188

#	ARTICLE	IF	CITATIONS
325	Structural network alterations and neurological dysfunction in cerebral amyloid angiopathy. <i>Brain</i> , 2015, 138, 179-188.	3.7	145
326	The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer's disease. <i>Journal of Prevention of Alzheimer's Disease</i> , 2015, 2, 242-253.	1.5	14
327	Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an 11C altoprane positron emission tomography study. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 52.	3.0	29
328	Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 719-728.	1.2	51
329	The A4 Study: Stopping AD Before Symptoms Begin?. <i>Science Translational Medicine</i> , 2014, 6, 228fs13.	5.8	588
330	Amyloid and <i>APOE</i> $\epsilon$ 4 interact to influence short-term decline in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1760-1767.	1.5	246
331	P3-266: NEUROPSYCHIATRIC SYMPTOMS AND FUNCTIONAL CONNECTIVITY IN MILD COGNITIVE IMPAIRMENT AND COGNITIVELY NORMAL ELDERLY. , 2014, 10, P729-P729.		0
332	Synergistic Effect of $\beta$ -Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. <i>JAMA Neurology</i> , 2014, 71, 1379.	4.5	273
333	Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults. <i>Journal of Neuroscience</i> , 2014, 34, 5200-5210.	1.7	65
334	Subjective Cognitive Concerns and Neuropsychiatric Predictors of Progression to the Early Clinical Stages of Alzheimer Disease. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1642-1651.	0.6	167
335	The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials. <i>Neuron</i> , 2014, 84, 608-622.	3.8	568
336	Microfluidic continuous-flow radiosynthesis of [ <sup>18</sup> F]FPEB suitable for human PET imaging. <i>MedChemComm</i> , 2014, 5, 432-435.	3.5	37
337	Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 291-300.	1.2	38
338	Regional Cortical Thinning Predicts Worsening Apathy and Hallucinations Across the Alzheimer Disease Spectrum. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1168-1179.	0.6	86
339	P1-180: A NEW PERFORMANCE-BASED ACTIVITIES OF DAILY LIVING INSTRUMENT FOR EARLY ALZHEIMER'S DISEASE. , 2014, 10, P365-P365.		1
340	O1-02-01: IMAGING TAU PATHOLOGY <i>IN VIVO</i> IN FTLD: INITIAL EXPERIENCE WITH [18F] T807 PET. <i>Alzheimer's and Dementia</i> , 2014, 10, P131.	0.4	3
341	IC-P-087: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P49-P50.		1
342	IC-P-213: IMAGING TAU PATHOLOGY <i>IN VIVO</i> IN FTLD: INITIAL EXPERIENCE WITH [18F] T807 PET. , 2014, 10, P115-P115.		3

#	ARTICLE	IF	CITATIONS
343	IC-P-152: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P87-P87.		0
344	P1-301: OLFACTORY IDENTIFICATION AND ALZHEIMER'S DISEASE BIOMARKERS IN CLINICALLY NORMAL ELDERLY. , 2014, 10, P422-P422.		0
345	F2-02-03: TAU AND AB DEPOSITS RELATE TO DISTINCTIVE FUNCTIONAL CONNECTIVITY DISRUPTIONS IN THE ELDERLY BRAIN. , 2014, 10, P159-P160.		3
346	O4-12-04: DETECTING COGNITIVE PROFILES IN THE BIOMARKER STAGES OF PRECLINICAL AD. , 2014, 10, P276-P276.		0
347	P2-246: GREATER SUBJECTIVE COGNITIVE CONCERNS CORRESPOND WITH ADVANCING STAGES OF PRECLINICAL AD. , 2014, 10, P566-P566.		1
348	The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related Functional Alterations of the Encoding/Retrieval Flip in Cognitively Normal Older Adults. Cerebral Cortex, 2013, 23, 1317-1328.	1.6	41
349	Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. Alzheimer's and Dementia, 2013, 9, e106-9.	0.4	90
350	Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's and Dementia, 2013, 9, e-1-16.	0.4	443
351	Functional Connectivity in Alzheimer's Disease: Measurement and Meaning. Biological Psychiatry, 2013, 74, 318-319.	0.7	8
352	O5-04-01: Pittsburgh compound B binding and MRI findings in nondemented hypertensive patients with cognitive concerns or mild cognitive impairment. , 2013, 9, P835-P835.		0
353	O4-06-03: Genotype-phenotype studies examining the CD33 locus and amyloid biology. , 2013, 9, P692-P693.		0
354	Florbetapir (F18â€AVâ€45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimer's and Dementia, 2013, 9, S72-83.	0.4	200
355	Update on Appropriate Use Criteria for Amyloid PET Imaging: Dementia Experts, Mild Cognitive Impairment, and Education. Journal of Nuclear Medicine, 2013, 54, 1011-1013.	2.8	61
356	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.5	174
357	Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Journal of Nuclear Medicine, 2013, 54, 476-490.	2.8	248
358	A concise radiosynthesis of the tau radiopharmaceutical, [ <sup>18</sup> F]T807. Journal of Labelled Compounds and Radiopharmaceuticals, 2013, 56, 736-740.	0.5	70
359	Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006213-a006213.	2.9	502
360	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.4	1

#	ARTICLE	IF	CITATIONS
361	Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. <i>Neuropsychologia</i> , 2012, 50, 2880-2886.	0.7	379
362	Amyloid $\beta$ associated cortical thinning in clinically normal elderly. <i>Annals of Neurology</i> , 2011, 69, 1032-1042.	2.8	306
363	Functional Alterations in Memory Networks in Early Alzheimer's Disease. <i>NeuroMolecular Medicine</i> , 2010, 12, 27-43.	1.8	497
364	Cortical Hubs Revealed by Intrinsic Functional Connectivity: Mapping, Assessment of Stability, and Relation to Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2009, 29, 1860-1873.	1.7	2,576
365	Amyloid Deposition Is Associated with Impaired Default Network Function in Older Persons without Dementia. <i>Neuron</i> , 2009, 63, 178-188.	3.8	899
366	Disruption of Functional Connectivity in Clinically Normal Older Adults Harboring Amyloid Burden. <i>Journal of Neuroscience</i> , 2009, 29, 12686-12694.	1.7	530
367	Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. <i>Annals of Neurology</i> , 2007, 62, 229-234.	2.8	465
368	Amyloid imaging of alzheimer's disease using pittsburgh compound B. <i>Current Neurology and Neuroscience Reports</i> , 2006, 6, 496-503.	2.0	21
369	Imaging Dementia with SPECT. <i>Annals of the New York Academy of Sciences</i> , 1991, 620, 165-174.	1.8	8
370	Preclinical Prediction of AD: Relation Between Neuropsychological and Neuroimaging Findings. , 0, , 97-110.		1